Cargando…
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
BACKGROUND: The current chemotherapy regimens may extend survival for patients with metastatic bladder cancer (BCa) for a few months, but eventually most patients succumb to disease because they develop resistance to their chemotherapy. METHODS: TCGA human clinical sample survey and urothelial tumor...
Autores principales: | Huang, Chi-Ping, Chen, Jinbo, Chen, Chi-Cheng, Liu, Guodong, Zhang, Yong, Messing, Edward, Yeh, Shuyuan, Chang, Chawnshang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592003/ https://www.ncbi.nlm.nih.gov/pubmed/31234917 http://dx.doi.org/10.1186/s13046-019-1258-0 |
Ejemplares similares
-
Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression
por: Izumi, Kouji, et al.
Publicado: (2013) -
AB130. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway
por: He, Dalin, et al.
Publicado: (2014) -
Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals
por: Lin, ChangYi, et al.
Publicado: (2015) -
ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
por: Tian, Hao, et al.
Publicado: (2021) -
New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
por: Lin, Shin-Jen, et al.
Publicado: (2016)